

Cara Haymaker

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3026306/publications.pdf>

Version: 2024-02-01

80
papers

5,982
citations

94433

37
h-index

82547

72
g-index

84
all docs

84
docs citations

84
times ranked

10305
citing authors

#	ARTICLE	IF	CITATIONS
1	Isolation and Maintenance of Tumor-Infiltrating Lymphocytes for Translational and Clinical Applications: Established Methods and New Developments. <i>Methods in Molecular Biology</i> , 2022, 2435, 43-71.	0.9	0
2	Hallmarks of Resistance to Immune-Checkpoint Inhibitors. <i>Cancer Immunology Research</i> , 2022, 10, 372-383.	3.4	36
3	Distinct Immune Gene Programs Associated with Host Tumor Immunity, Neoadjuvant Chemotherapy, and Chemoimmunotherapy in Resectable NSCLC. <i>Clinical Cancer Research</i> , 2022, 28, 2461-2473.	7.0	9
4	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
5	Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception. <i>Clinical Cancer Research</i> , 2022, 28, 1938-1947.	7.0	11
6	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
7	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
8	Pathological Response and Immune Biomarker Assessment in Non-Small-Cell Lung Carcinoma Receiving Neoadjuvant Immune Checkpoint Inhibitors. <i>Cancers</i> , 2022, 14, 2775.	3.7	5
9	Neoadjuvant Chemotherapy Increases Cytotoxic T Cell, Tissue Resident Memory T Cell, and B Cell Infiltration in Resectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 127-139.	1.1	48
10	Aurora kinase inhibition sensitizes melanoma cells to T-cell-mediated cytotoxicity. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1101-1113.	4.2	18
11	Identification of distinct immune landscapes using an automated nine-color multiplex immunofluorescence staining panel and image analysis in paraffin tumor tissues. <i>Scientific Reports</i> , 2021, 11, 4530.	3.3	27
12	Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial. <i>Nature Medicine</i> , 2021, 27, 504-514.	30.7	357
13	Identification of bacteria-derived HLA-bound peptides in melanoma. <i>Nature</i> , 2021, 592, 138-143.	27.8	187
14	Tiltsotolimod with Ipilimumab Drives Tumor Responses in Anti-PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	9.4	32
15	Pilot Clinical Trial of Perioperative Durvalumab and Tremelimumab in the Treatment of Resectable Colorectal Cancer Liver Metastases. <i>Clinical Cancer Research</i> , 2021, 27, 3039-3049.	7.0	28
16	Immuno-profiling and cellular spatial analysis using five immune oncology multiplex immunofluorescence panels for paraffin tumor tissue. <i>Scientific Reports</i> , 2021, 11, 8511.	3.3	24
17	Characterization of the Immune Landscape of EGFR-Mutant NSCLC Identifies CD73/Adenosine Pathway as a Potential Therapeutic Target. <i>Journal of Thoracic Oncology</i> , 2021, 16, 583-600.	1.1	62
18	Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3584-3594.	7.0	26

#	ARTICLE	IF	CITATIONS
19	Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. <i>Nature Communications</i> , 2021, 12, 2722.	12.8	74
20	Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial. <i>Clinical and Translational Medicine</i> , 2021, 11, e491.	4.0	26
21	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. <i>Clinical Cancer Research</i> , 2021, 27, 5062-5071.	7.0	8
22	Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. <i>Nature Communications</i> , 2021, 12, 5045.	12.8	42
23	Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. <i>Clinical Cancer Research</i> , 2021, 27, 5912-5921.	7.0	57
24	Engineered T-cell Receptor T Cells for Cancer Immunotherapy. <i>Cancer Immunology Research</i> , 2021, 9, 1252-1261.	3.4	16
25	Evolution of Genomic and T-cell Repertoire Heterogeneity of Malignant Pleural Mesothelioma Under Dasatinib Treatment. <i>Clinical Cancer Research</i> , 2020, 26, 5477-5486.	7.0	15
26	Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. <i>Cancer Immunology Research</i> , 2020, 8, 794-805.	3.4	17
27	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661.	12.8	124
28	Procedural Requirements and Recommendations for Multiplex Immunofluorescence Tyramide Signal Amplification Assays to Support Translational Oncology Studies. <i>Cancers</i> , 2020, 12, 255.	3.7	58
29	Next-Generation Immunotherapies to Improve Anticancer Immunity. <i>Frontiers in Pharmacology</i> , 2020, 11, 566401.	3.5	8
30	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	9.4	158
31	Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1747-1757.	4.2	16
32	Exposure to anti-PD-1 causes functional differences in tumor-infiltrating lymphocytes in rare solid tumors. <i>European Journal of Immunology</i> , 2019, 49, 2245-2251.	2.9	4
33	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R β -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721.	9.4	180
34	Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer. <i>JAMA Oncology</i> , 2019, 5, 67.	7.1	344
35	TIL therapy and anti-CTLA4: can they co-exist?. <i>Oncotarget</i> , 2019, 10, 1-2.	1.8	1
36	The RNA-binding Protein MEX3B Mediates Resistance to Cancer Immunotherapy by Downregulating HLA-A Expression. <i>Clinical Cancer Research</i> , 2018, 24, 3366-3376.	7.0	73

#	ARTICLE	IF	CITATIONS
37	The Effect of Topoisomerase I Inhibitors on the Efficacy of T-Cell-Based Cancer Immunotherapy. <i>Journal of the National Cancer Institute</i> , 2018, 110, 777-786.	6.3	58
38	RNA editing derived epitopes function as cancer antigens to elicit immune responses. <i>Nature Communications</i> , 2018, 9, 3919.	12.8	120
39	Combined Analysis of Antigen Presentation and T-cell Recognition Reveals Restricted Immune Responses in Melanoma. <i>Cancer Discovery</i> , 2018, 8, 1366-1375.	9.4	80
40	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
41	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2018, 41, 399-405.	2.4	32
42	Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches. , 2018, 6, 48.		126
43	Metastatic Melanoma Patient Had a Complete Response with Clonal Expansion after Whole Brain Radiation and PD-1 Blockade. <i>Cancer Immunology Research</i> , 2017, 5, 100-105.	3.4	46
44	4-1BB Enhanced Expansion of CD8+ TIL from Triple-Negative Breast Cancer Unveils Mutation-Specific CD8+ T Cells. <i>Cancer Immunology Research</i> , 2017, 5, 439-445.	3.4	45
45	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
46	4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 7263-7275.	7.0	41
47	Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. <i>Scientific Reports</i> , 2017, 7, 13380.	3.3	208
48	Absence of Grail promotes CD8+ T cell anti-tumour activity. <i>Nature Communications</i> , 2017, 8, 239.	12.8	22
49	TCR Repertoire Intratumor Heterogeneity in Localized Lung Adenocarcinomas: An Association with Predicted Neoantigen Heterogeneity and Postsurgical Recurrence. <i>Cancer Discovery</i> , 2017, 7, 1088-1097.	9.4	160
50	Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. <i>Clinical Cancer Research</i> , 2017, 23, 6151-6164.	7.0	58
51	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>OncImmunology</i> , 2017, 6, e1321187.	4.6	45
52	A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes. <i>Frontiers in Immunology</i> , 2017, 8, 908.	4.8	50
53	Single-cell profiling of dynamic cytokine secretion and the phenotype of immune cells. <i>PLoS ONE</i> , 2017, 12, e0181904.	2.5	39
54	Selective inhibition of autoimmune exacerbation while preserving the anti-tumor clinical benefit using IL-6 blockade in a patient with advanced melanoma and Crohn's disease: a case report. <i>Journal of Hematology and Oncology</i> , 2016, 9, 81.	17.0	62

#	ARTICLE	IF	CITATIONS
55	A case report of Grover's disease from immunotherapy—a skin toxicity induced by inhibition of CTLA-4 but not PD-1. , 2016, 4, 55.		50
56	Novel algorithmic approach predicts tumor mutation load and correlates with immunotherapy clinical outcomes using a defined gene mutation set. BMC Medicine, 2016, 14, 168.	5.5	106
57	Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma. Scientific Reports, 2016, 6, 35848.	3.3	127
58	Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy. Cancer Discovery, 2016, 6, 202-216.	9.4	1,158
59	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. Oncoimmunology, 2016, 5, e1136044.	4.6	55
60	The beneficial effects of a gas-permeable flask for expansion of Tumor-Infiltrating lymphocytes as reflected in their mitochondrial function and respiration capacity. Oncoimmunology, 2016, 5, e1057386.	4.6	22
61	Immune-Modulation by Epidermal Growth Factor Receptor Inhibitors: Implication on Anti-Tumor Immunity in Lung Cancer. PLoS ONE, 2016, 11, e0160004.	2.5	33
62	BTLA marks a less-differentiated tumor-infiltrating lymphocyte subset in melanoma with enhanced survival properties. Oncoimmunology, 2015, 4, e1014246.	4.6	50
63	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. Cancer Immunology Research, 2015, 3, 1201-1206.	3.4	29
64	Batf is important for IL-4 expression in T follicular helper cells. Nature Communications, 2015, 6, 7997.	12.8	114
65	Activation and Propagation of Tumor-infiltrating Lymphocytes on Clinical-grade Designer Artificial Antigen-presenting Cells for Adoptive Immunotherapy of Melanoma. Journal of Immunotherapy, 2014, 37, 448-460.	2.4	47
66	Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Rationale and Issues for Further Clinical Development. BioDrugs, 2014, 28, 421-437.	4.6	21
67	Identification of predictive biomarker signatures in melanoma tumors associated with response to tumor-infiltrating lymphocyte (TIL) therapy. , 2013, 1, .		0
68	Development of novel combinations of targeted and immunotherapies by understanding immune resistance using a high throughput assay of T cell mediated cytotoxicity. , 2013, 1, .		0
69	Antigen-Specific Effector CD4 T Lymphocytes School Lamina Propria Dendritic Cells To Transfer Innate Tolerance. Journal of Immunology, 2013, 190, 6004-6014.	0.8	6
70	Adoptive T-Cell Therapy Using Autologous Tumor-Infiltrating Lymphocytes for Metastatic Melanoma. Cancer Journal (Sudbury, Mass), 2012, 18, 160-175.	2.0	176
71	PD-1 and BTLA and CD8 ⁺ T-cell "exhaustion" in cancer. Oncoimmunology, 2012, 1, 735-738.	4.6	71
72	Bone Marrow-Derived IL-13R ⁺ Positive Thymic Progenitors Are Restricted to the Myeloid Lineage. Journal of Immunology, 2012, 188, 3208-3216.	0.8	15

#	ARTICLE	IF	CITATIONS
73	Mechanisms Underlying Antigen-Specific Tolerance of Stable and Convertible Th17 Cells During Suppression of Autoimmune Diabetes. <i>Diabetes</i> , 2012, 61, 2054-2065.	0.6	19
74	T Cell Dynamics during Induction of Tolerance and Suppression of Experimental Allergic Encephalomyelitis. <i>Journal of Immunology</i> , 2011, 187, 3979-3986.	0.8	13
75	FoxP3+ROR γ t+ T Helper Intermediates Display Suppressive Function against Autoimmune Diabetes. <i>Journal of Immunology</i> , 2010, 184, 3377-3385.	0.8	81
76	APCs Expressing High Levels of Programmed Death Ligand 2 Sustain the Development of CD4 T Cell Memory. <i>Journal of Immunology</i> , 2010, 185, 3149-3157.	0.8	7
77	In Trans T Cell Tolerance Diminishes Autoantibody Responses and Exacerbates Experimental Allergic Encephalomyelitis. <i>Journal of Immunology</i> , 2008, 180, 1508-1516.	0.8	3
78	Fetal Exposure to High-Avidity TCR Ligand Enhances Expansion of Peripheral T Regulatory Cells. <i>Journal of Immunology</i> , 2008, 181, 73-80.	0.8	19
79	Delayed maturation of an IL-12-producing dendritic cell subset explains the early Th2 bias in neonatal immunity. <i>Journal of Experimental Medicine</i> , 2008, 205, 2269-2280.	8.5	121
80	Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0